
|Articles|February 3, 2005
Company withdraws application for stress incontinence drug
Eli Lilly said it has withdrawn its new drug application for duloxetine hydrochloride for the treatment of stress urinary incontinence.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC
5






